Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Xencor Inc Director's Dealing 2021

Sep 8, 2021

32653_dirs_2021-09-08_ba19705b-1602-4323-8af1-2625fe804b9c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Inmune Bio, Inc. (INMB)
CIK: 0001711754
Period of Report: 2021-09-03

Reporting Person: Xencor Inc (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-09-03 Common Stock M 108000 $7.80 Acquired 1885533 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-09-03 Stock Option (Right to Buy) $7.80 M 108000 Disposed 2021-09-08 Common Stock (108000) Direct

Footnotes

F1: The shares underlying this option vested in 36 equal monthly installments beginning on April 3, 2018.